As MARCH5 can regulate mitotic apoptosis in a MCL1-independent mechanism, it is possible that targeting MARCH5 can promote sensitivity to antimitotic treatments even in cancer cells overexpressing MCL1. This evidence concerns the gene MCL1 and cancer.